Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27977591 | 1.00 | CYP2A6 (0.41) | CYP2A6CYP3A4CHRNB2CHRNA4CHRNB4 | |
| Benzene SCHEMBL28093687 | 0.98 | MAPT (0.41) | CYP2A6CYP3A4CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29137307 | 0.98 | CYP2A6 (0.40) | CYP2A6CYP3A4CHRNB2CHRNA4CHRNB4 | |
| Propane SCHEMBL27699446 | 0.94 | ELANE (0.41) | CYP2A6CYP3A4CHRNB2CHRNA4CHRNB4 | |
| Bromobenzene SCHEMBL28160069 | 0.89 | HTT (0.39) | CYP2A6CYP3A4CHRNB2CHRNA4CHRNB4 | |
| N-Propyl Bromide SCHEMBL27977576 | 0.88 | ELANE (0.38) | CYP2A6CYP3A4CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2049800 | 0.81 | MAPT (0.33) | CYP3A4HTTMAPTMAPK1 | |
| SCHEMBL4140323 | 0.79 | MAPT (0.32) | HTTMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL29103226 | 0.79 | NPC1 (0.35) | HTTMAPTMAPK1 | |
| SCHEMBL1652919 | 0.79 | CHKA (0.40) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | claimed |
| EP-4720040-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| CN-119463170-A | Preparation method and application of triazinyl ionic organic polymer | 昆明理工大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-119264042-A | Cyclopentane derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024246522-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | LARIO THERAPEUTICS LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| CN-117651698-A | Pyridone MK2 inhibitors and uses thereof | 新特拉有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2023-03-14 | — | — | US | disclosed |
| CN-115702145-A | Substituted pyridines for the treatment of inflammatory diseases | 戈萨默生物服务公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-114456175-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114456176-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | CYP2A6 1059/4885CYP3A4 699/4885CHRNB2 1980/4885 |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | CYP2A6 1386/4885CYP3A4 1387/4885CHRNB2 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.